Old Web
English
Sign In
Acemap
>
authorDetail
>
John E. Kraus
John E. Kraus
GlaxoSmithKline
Medicine
Psychiatry
Duchenne muscular dystrophy
Population
Phases of clinical research
4
Papers
394
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
2018
Neuromuscular Disorders
Nathalie Goemans
Eugenio Mercuri
Elena Belousova
Hirofumi Komaki
Alberto Dubrovsky
Craig M. McDonald
John E. Kraus
A. Lourbakos
Zhengning Lin
G. Campion
Susanne X. Wang
Craig Campbell
Show All
Source
Cite
Save
Citations (64)
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
2014
Lancet Neurology
Thomas Voit
Haluk Topaloglu
Volker Straub
Francesco Muntoni
Nicolas Deconinck
Giles G Campion
Sjef J. de Kimpe
Michelle Eagle
M. Guglieri
Steve S Hood
Lia Liefaard
Afrodite Lourbakos
A Morgan
Joanna Nakielny
Naashika Quarcoo
V. Ricotti
Katie Rolfe
Laurent Servais
C. Wardell
Rosamund Wilson
Pádraig Wright
John E. Kraus
Show All
Source
Cite
Save
Citations (243)
Differences in Medication Adherence and Healthcare Resource Utilization Patterns : Older versus Newer Antidepressant Agents in Patients with Depression and/or Anxiety Disorders
2008
CNS Drugs
David V. Sheehan
Matthew S. Keene
Michael Eaddy
Stan Krulewicz
John E. Kraus
David J. Carpenter
Show All
Source
Cite
Save
Citations (74)
Managing treatment resistant violent adolescents: a step forward by substituting seclusion for mechanical restraint?
2008
Administration and Policy in Mental Health
Thomas C. Larson
Brian Sheitman
John E. Kraus
James P. Mayo
LuAnn Leidy
Show All
Source
Cite
Save
Citations (13)
1